Abstract
BmK AngM1, a scorpion peptide isolated from Buthus martensii Karch was reported to exhibit potential analgesic effect. But the relative low content of this toxin in crude venom limits its further characterization. In this study, we constructed an expression vector and transformed into E.coli. The BmK AngM1 was expressed as a fusion protein in the soluble fraction and was purified by Nickel affinity chromatography. Subsequently, the purified fusion protein was cleaved by enterokinase and was further purified by reverse-phase HPLC. We purified 25 mg recombinant BmK AngM1 (rBmK AngM1) from 1 L bacterial culture. The molecular weight of rBmK AngM1 determined by ESI-MS was 7240.4 Da which was the expected size for correctly processed. Analgesic bioassay studies of rBmK AngM1 exhibited its potential analgesic effect comparable to that of the natural BmK AngM1 peptide.
Keywords: Analgesia, BmK AngM1, Buthus martensii Karch, Expression
Protein & Peptide Letters
Title: High-Level Expression and Purification of an Analgesic Peptide from Buthus martensii Karch
Volume: 14 Issue: 3
Author(s): Z. Cao, W. Wang, X. Xiao, K. Chen, X. Liang and D. Yu
Affiliation:
Keywords: Analgesia, BmK AngM1, Buthus martensii Karch, Expression
Abstract: BmK AngM1, a scorpion peptide isolated from Buthus martensii Karch was reported to exhibit potential analgesic effect. But the relative low content of this toxin in crude venom limits its further characterization. In this study, we constructed an expression vector and transformed into E.coli. The BmK AngM1 was expressed as a fusion protein in the soluble fraction and was purified by Nickel affinity chromatography. Subsequently, the purified fusion protein was cleaved by enterokinase and was further purified by reverse-phase HPLC. We purified 25 mg recombinant BmK AngM1 (rBmK AngM1) from 1 L bacterial culture. The molecular weight of rBmK AngM1 determined by ESI-MS was 7240.4 Da which was the expected size for correctly processed. Analgesic bioassay studies of rBmK AngM1 exhibited its potential analgesic effect comparable to that of the natural BmK AngM1 peptide.
Export Options
About this article
Cite this article as:
Cao Z., Wang W., Xiao X., Chen K., Liang X. and Yu D., High-Level Expression and Purification of an Analgesic Peptide from Buthus martensii Karch, Protein & Peptide Letters 2007; 14 (3) . https://dx.doi.org/10.2174/092986607780090883
DOI https://dx.doi.org/10.2174/092986607780090883 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pyrazolo-Triazolo-Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes?
Current Pharmaceutical Design Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings
Current Pharmaceutical Design NMDA Receptors and Learning and Memory Processes
Current Drug Targets Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Effect of Valerian Extract on GABRB3 Gene MRNA Expression and Sedation in BALB/C Mice
Current Bioactive Compounds Early Intervention in Psychosis: Rationale, Results and Implications for Treatment of Adolescents at Risk
Adolescent Psychiatry Pharmacological Treatment of Cannabis Dependence
Current Pharmaceutical Design Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets A Review on the Arylpiperazine Derivatives as Potential Therapeutics for the Treatment of Various Neurological Disorders
Current Drug Targets Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Psychiatric Disorders and TRP Channels: Focus on Psychotropic Drugs
Current Neuropharmacology Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Glycosphingolipid Structure and Function in Membranes
Current Organic Chemistry Video Game Addiction: Past, Present and Future
Current Psychiatry Reviews Statins, Mevalonate Pathway and its Intermediate Products in Placental Development and Preeclampsia
Current Molecular Pharmacology Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Current Pharmaceutical Design Potential Interaction Between Valproic Acid and Doripenem
Current Drug Safety